6.48

2.05% +0.13

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is currently priced at $6.48, with a 24-hour trading volume of 860.10K. It has seen a +2.05% increased in the last 24 hours and a -16.17% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $6.44 pivot point. If it approaches the $6.53 resistance level, significant changes may occur.

Previous Close:

$6.35

Open:

$6.36

24h Volume:

860.10K

Market Cap:

$397.79M

Revenue:

Net Income/Loss:

$-209.96M

P/E Ratio:

-2.1818

EPS:

-2.97

Net Cash Flow:

$-176.27M

1W Performance:

+2.37%

1M Performance:

-16.17%

6M Performance:

-54.65%

1Y Performance:

-62.97%

1D Range:

$6.22

$6.76

52W Range:

$5.86

$24.81

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1189)

Industry

Biotechnology (685)

Phone

781-995-2443

Address

18 Commerce Way, Woburn, MA

Employee

Twitter

@Replimune

Next Earnings Date

2024-05-16

Latest SEC Filings

REPL's Discussions on Twitter

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting

GlobeNewswire Inc.

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

GlobeNewswire Inc.

How Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%

Zacks Investment Research

What Makes Replimune Group, Inc. (REPL) a New Buy Stock

Zacks Investment Research

Wall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?

Zacks Investment Research

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

Replimune Group Inc Stock (REPL) Financials Data

Replimune Group Inc (REPL) Net Income 2024

REPL net income (TTM) was -$209.96 million for the quarter ending December 31, 2023, a -33.95% decrease year-over-year.

Replimune Group Inc (REPL) Cash Flow 2024

REPL recorded a free cash flow (TTM) of -$176.27 million for the quarter ending December 31, 2023, a -45.70% decrease year-over-year.

Replimune Group Inc (REPL) Earnings per Share 2024

REPL earnings per share (TTM) was -$3.16 for the quarter ending December 31, 2023, a -10.49% decline year-over-year.

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.